Nanjing Leads Biolabs Co., Ltd.HKEX: 9887

Voluntary announcement updated data from phase ii clinical study of lbl-024 (opamtistomig, pd-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line treatment for nsclc presented orally at wclc 2026

Sep 14, 2026 at 5:10 AM EDT · Issued by Nanjing Leads Biolabs Co., Ltd. via HKEXnews

Filed with HKEX · Stock code 9887 · Sep 14, 2026 at 5:10 AM EDT

6ix hasn’t read this filing yet.

Earlier from Nanjing Leads Biolabs

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion StageAug 24
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting TherapyAug 21
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy ImprovementAug 19
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy SignalsAug 5
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology FranchiseAug 2

Follow Nanjing Leads Biolabs into a list and get an email when it puts out news.